- recruitingTherapeutic confirmatory (Phase III)
A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months
This study is looking at a new treatment called efanesoctocog alfa for severe haemophilia A. It aims to see how it affects physical activity and joint health in patients aged 12 and over, comparing results over 24 months. It's a key step in understanding if this medicine helps people live more active lives.
Croatia · Norway · Italy - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
This study looks at a new treatment called efanesoctocog alfa for severe haemophilia A. It compares how it works in the body to other similar treatments. This helps us understand if it's as good or better at keeping blood clotting levels steady.
Germany · Spain · Italy - enrolling by invitation
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
This study looks at how well Esperoct® works and if it has side effects for men and boys with haemophilia A. Participants will receive their usual treatment and share information about their health over several years.
Austria · Bulgaria · Croatia - recruiting
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
This study looks at how well Octapharma's treatments (Nuwiq, Octanate, and Wilate) work in real life for children and young people with severe haemophilia A who haven't had much treatment before. It checks their safety and how they are used.
United States · Argentina · Azerbaijan - recruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
United States · Austria · Belgium - active not recruitingPHASE3
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
This study is testing a new medicine called Mim8 for people with haemophilia A, including those with inhibitors. Mim8 aims to prevent bleeding episodes by helping blood clot. It's for people already in other Mim8 studies.
United States · Austria · Belgium - not yet recruitingPHASE3
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
This study is looking at a new medicine called denecimig for adults with a rare bleeding condition called acquired haemophilia A. We want to see if it's safe and helps stop or treat bleeding. Participants would be in the study for up to about 1 year and 5 months.
United States · Argentina · Australia